Search hospitals > Michigan > Detroit
Josephine Ford Cancer Center at Henry Ford Hospital
Claim this profileDetroit, Michigan 48202
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Brain Tumor
Conducts research for Cancer
Conducts research for Nervous System Tumor
175 reported clinical trials
9 medical researchers
Summary
Josephine Ford Cancer Center at Henry Ford Hospital is a medical facility located in Detroit, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Brain Tumor, Cancer, Nervous System Tumor and other specialties. Josephine Ford Cancer Center at Henry Ford Hospital is involved with conducting 175 clinical trials across 167 conditions. There are 9 research doctors associated with this hospital, such as Ding Wang, Shirish Gadgeel, MD, Tobias Walbert, MD, PhD, MPH, and Philip Kuriakose, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage II
Top PIs
Ding WangHenry Ford Hospital6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cancer
47 reported clinical trials
104 drugs studied
Shirish Gadgeel, MDHenry Ford Hospital4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
19 reported clinical trials
30 drugs studied
Tobias Walbert, MD, PhD, MPHHenry Ford Hospital6 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
12 reported clinical trials
17 drugs studied
Philip Kuriakose, MDHenry Ford Health System4 years of reported clinical research
Studies Lymphoma
Studies Haemophilia A, Haemophilia B, Obesity
11 reported clinical trials
19 drugs studied
Clinical Trials running at Josephine Ford Cancer Center at Henry Ford Hospital
Cancer
Breast Cancer
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Myeloid Leukemia
Solid Tumors
Lung Cancer
Melanoma
Adult T-Cell Leukemia/Lymphoma
Metastatic Tumor
NVL-520
for ROS1-Positive Solid Tumors
This trial tests NVL-520, a new drug, for safety and effectiveness in patients with advanced ROS1-positive cancers. It targets those who haven't responded well to other treatments by blocking a protein that helps cancer cells grow. NVL-520 is being tested for its effectiveness in treating advanced ROS1-positive cancers, a targetable mutation in non-small cell lung cancer (NSCLC) that has seen various treatments like crizotinib and entrectinib.
Recruiting1 award Phase 1 & 2
Ziftomenib Combinations
for Acute Myeloid Leukemia
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Recruiting1 award Phase 19 criteria
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting1 award Phase 1 & 27 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Josephine Ford Cancer Center at Henry Ford Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.